期刊文献+

可溶性Tie2融合蛋白玻璃体腔注射对实验性视网膜血管新生和缺血性视网膜病变的影响 被引量:1

Suppression of experimental retinal neovascularization utilizing soluble Tie2 fusion protein
下载PDF
导出
摘要 目的:观察可溶性Tie2融合蛋白(soluble Tie2 fusion pro-tein,sTie-Fc)对视网膜血管新生(retinal neovascularization,RNV)的抑制作用,同时分析其对缺血性视网膜病变的影响。方法:将生后7d的C57BL/6幼鼠置于高氧箱中饲养5d取回至正常空气环境诱导RNV模型,生后12d和14d选取一眼玻璃体腔注入人sTie-Fc0.67μg,对侧眼在相同时点注入人IgG作为对照。生后17d处死动物行视网膜铺片和免疫组织化学染色检查,测量视网膜血管无灌注区的面积,计数RNV内皮细胞核数目,定量分析sTie-Fc对于缺血性视网膜病变以及实验性RNV形成的影响。结果:对照组和实验组均成功建立了RNV模型,实验组RNV的形成受到抑制(P<0.05),同时sTie-Fc也加重了RNV模型的缺血过程(P<0.05)。结论:sTie-Fc可以抑制实验性RNV的发展,提示拮抗Tie2可能成为治疗RNV有效的生物学方法之一,其可能加重缺血性视网膜病变的潜在副作用需进一步探讨。 AIM: To investigate the effects of neutralizing Tie2 on retinal neovascularization (RNV) and ischemic retinopathy in the mouse model of oxygen-induced retinopathy (OIR). METHODS: C57BL/6 mice at postnatal day 7 were exposed to 750mL/L oxygen for 5 days and allowed to recover in room air to induce RNV. At the 12th and 14th day, the animals were intravitreally injected with 0.67μg soluble Tie2 fusion protein (sTie-Fc). Retinal fluorescein angiography and immunohistochemical staining were used to assess the development of ischemic retinopathy and experimental RNV quantitatively at the 17th day, by measuring the area of vascular obliteration and counting the number of preretinal nuclei. RESULTS: sTie-Fc significantly inhibited the formation of RNV (P〈 0.05) and aggravated the ischemia ( P 〈 0.05) compared with control mice. CONCLUSION : Our findings suggest that Tie2 may be a promising potential target for antiangiogenesis therapy for RNV. Further research is needed to decrease the undesirable effect of inhibiting retinal revascularization.
作者 张含 刘哲丽
出处 《国际眼科杂志》 CAS 2008年第3期502-504,共3页 International Eye Science
关键词 视网膜血管新生 缺血性视网膜病变 TIE2 retinal neovascularization ischemic reti- nopathy Tie2
  • 相关文献

参考文献3

二级参考文献135

共引文献38

同被引文献13

  • 1Adlerereutz H,Markkanen H,Watanabe S.Plasma concentra-tionsof phyto-oestxogens in Japanese men[J].Lancet,1993,342(8881):1209-1210.
  • 2Kovach JL,Schwartz SG,Hickey M,Puliafito CA.Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intxavitreal bevacizumab[J].Ophthalmic Surg Lasers Imaging,2009,40(1):77-79.
  • 3Nehil M,Paquette J,Tokuyasu T,McCormick F.High mobility group box I promotes tumor cell migration through epigenetic silencing of semaphorin 3A[J].Oncogene,2014,33(44):5151-5162.
  • 4El-Asrar AM,Nawaz MI,Kangave D,Geboes K,Ola MS,Ahmad Sfetal.High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy[J].Jtfoi Vis,2011,17(6):1829-1838.
  • 5Van Beijnum JR,Buurman WA,Griffioen AW.Convergence and amplification of toll-like receptor(TLR)and receptor for advanced glycation end products(RAGE)signaling pathways via high mobility group BI(HMGBl)[J].Angiogenesis,2008,11(1):91-99.
  • 6Vannay A,Dunai G,Banyasz I,Szab6 M,Vamos R,Treszl k,et al.Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity[J].Pediatr Res,2005,57(3):396-398.
  • 7Eltzschig HK,Kohler D,Eckle T,Kong T,Robson SC,Colgan SP.Central role of Spl-regulated CD39 in hypoxia/ischemia protection[J].Blood,2009,113(1):224-232.
  • 8Mitola S,Belleri M,Urbinati C,Coltrini D,Sparatore B,Pedrazzi M,et al.Cutting edge:extracellular high mobility group box-1 protein is a proangiogenic cytokine[J].J Immunol,2006,176(1):12-15.
  • 9Biscetti F,Straface G,De Cristofaro R,Lancellotti S,Rizzo P,A-rena V,et al.High mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism[J].Diabetes,2010,59(6):1496-1505.
  • 10Mohammad G,Siddiquei MM,Othman A,Al-Shabrawey M,Abu El-Asrar AM.High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina[J].Eocp Eye Res,2013,107(1):101-109.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部